.AstraZeneca has made use of artificial intelligence to devise an one-of-a-kind biomarker for its Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), intending to differentiate the antibody-drug conjugate
Read moreAN 2 fifty percents roll call, quits phase 3 test after data let down
.AN2 Rehabs is reviewing its company in reaction to lackluster midphase data, pledging to lay off half its own staff members and cease a stage
Read moreALX’s waning CD47 action rate delivers sell spiraling down
.ALX Oncology’s stage 2 stomach cancer cells feedback fee has deteriorated. After seeing its CD47 blocker simply beat management over the 1st half of the
Read moreAC Immune observes ‘spots’ prospective in Alzheimer’s medication information
.After greater than 20 years of work on neurodegenerative conditions, Swiss biotech air conditioning Immune system insurance claims it can have a game changer on
Read more